Sterility Tests

The Sterility Test is a compendial microbiological method, defined in USP <71> and other major pharmacopeias, to determine whether a parenteral drug product contains viable contaminating microorganisms (bacteria, yeast, or fungi). It is a critical final release test for all sterile injectable products and a non-negotiable requirement for patient safety.

• Legacy Technique: Open Cleanroom Operations. Historically, sterility tests were performed in an open cleanroom environment (e.g., in a laminar flow hood), which carried a significant risk of accidental contamination leading to false positive results.
• Established Standard: Membrane Filtration performed in a controlled Grade A environment (either a laminar airflow cleanroom or, increasingly, a fully enclosed isolator). Isolators are preferred due to their reduced risk of extraneous contamination. Closed-system, single-use filtration devices (e.g., MilliporeSigma Steritest™) are commonly used.
• Future: Rapid Microbiological Methods (RMMs). While USP <71> and Ph. Eur. 2.6.1 still require the 14-day sterility test, RMMs such as ATP bioluminescence, solid-phase cytometry, and nucleic acid amplification are being explored for supplemental use and conditional release, particularly for time-sensitive modalities such as autologous cell therapies. The Ph. Eur. 5.1.6 chapter provides detailed guidance for validating these alternative methods.

The principle of the standard Membrane Filtration method is a three-step process:

Concentration: The product is passed through a sterile membrane filter with a defined pore size (typically 0.45 µm), which traps any microorganisms on its surface.

Rinsing: The filter is rinsed with a sterile fluid to wash away any antimicrobial components of the drug product that could inhibit growth.

Cultivation: The filter is aseptically transferred to sterile, nutrient-rich liquid media and incubated for 14 days, allowing any trapped, viable organisms to multiply into a visually detectable colony or cause turbidity.

• Output: A qualitative, binary, visual observation for each test unit and medium: "Growth" (turbidity observed) or "No Growth" (media remains clear).
• Interpretation: If growth is observed in any test unit, the sterility test is considered a failure. A full root cause investigation, including microbial identification and review of aseptic process simulation (media fill) history, is then required to assess whether the contamination arose from the product or from extraneous laboratory factors.

• Compendial Standard: It is the definitive, globally accepted standard test for sterility referenced in all major pharmacopeias.
• Broad Detection: The dual-media, dual-temperature approach is designed to detect a very wide range of common bacteria, yeast, and molds.

Non-detection of fastidious or VBNC (viable but non-culturable) organisms is a known limitation.

The 14-day incubation period is a major industry bottleneck, delaying product release and tying up valuable inventory.

High Risk of False Positives: The test involves numerous aseptic manipulations. Any breach in technique or the sterile environment can introduce a contaminant, leading to a false positive result and a costly, time-consuming investigation.

The most critical validation step, as defined in USP <71>, is the Method Suitability Test, commonly known as the Bacteriostasis and Fungistasis (B/F) test.

• Purpose: To prove that any residual drug product in the test system does not inhibit the growth of microorganisms.
• Procedure: The standard test is performed, but a small number (<100 CFU) of challenge microorganisms (e.g., Staphylococcus aureus, Bacillus subtilis, Pseudomonas aeruginosa, Clostridium sporogenes, Candida albicans, Aspergillus brasiliensis) are added to the test media.
• Acceptance Criteria: The microorganisms must grow to a visible extent, proving that if a contaminant were present in the actual product, it would be able to grow and be detected.

• mAbs & AAVs: The Membrane Filtration method is standard. The primary consideration is passing the B/F test to show the formulated drug product does not inhibit microbial growth.
• Cell Therapies: Because of short shelf-life, regulators may permit conditional release based on interim negative results (e.g., at 3 or 7 days), but only under a risk-based approach and with prior regulatory agreement. The full 14-day incubation is still required post-administration. Robust controls—such as validated aseptic processing, RMMs, and extensive environmental monitoring—are mandatory to support this approach.